TK2d

News

People living with thymidine kinase 2 deficiency (TK2d), a vanishingly rare and often fatal genetic disorder, finally have an approved therapy.

News

UCB's experimental medicine for TK2d, currently under regulatory review, offers hope to patients with the devastating rare disease.

Patients

At LSX World Congress 2026 in Lisbon, Portugal, web editor Nicole Raleigh spoke with Hans Schambye, CEO of BOOST Pharma.

Sales & Marketing

As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.